Notably, a previous study showed that gefitinib plus platinum doublet showed better clinical outcomes in terms of PFS and OS compared with gefitinib alone in EGFR-mutant NSCLC [56]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.